ALX Oncology is a clinical-stage biotechnology company developing novel immunotherapy and targeted cancer treatments. The company's pipeline includes evorpacept, a CD47-blocking fusion protein designed to enhance immune attack on cancer cells while minimizing blood-related side effects, and ALX2004, an antibody-drug conjugate targeting EGFR-expressing tumors. ALX Oncology has no product revenues and is funded through equity and debt financing while it advances its candidates through clinical trials across multiple oncology indications, including gastric cancer, breast cancer, non-Hodgkin lymphoma, and solid tumors; the company plans to commercialize approved therapies independently or through partnerships.